Even so, recent data from the United States T1D Exchange (T1DX) Registry indicates that only 17% of youth and 21% of adults meet the American Diabetes Association (ADA) recommended hemoglobin A1c (HbA1c) treatment target.1 Automation of insulin delivery with a hybrid closed-loop (HCL) system has the potential to improve glycemic outcomes and reduce the burden of care for people with T1D. This evidence concerns the gene INS and type 1 diabetes mellitus.